Screening of mortality in transplant patients using an assay for immune function

Transplant Immunology

Volumn 24, Issue 4, 2011, Pages 246-250

  Berglund, David ^a   Bengtsson, Mats ^a   Biglarnia, Alireza ^a   Berglund, Erik ^a   Yamamoto, Shinji ^a   von Zur Mühlen, Bengt ^a   Lorant, Tomas ^a   Tufveson, Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

ImmuKnow; Mortality; Overimmunosuppression; Rejection; Screening

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; IMMUKNOW IMMUNE CELL FUNCTION ASSAY; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

CAUSE OF DEATH; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INFECTION; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION; PREVALENCE; RISK;

EID: 79955472274     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2010.12.005     Document Type: Article

References (31)

1. Kirkman R.L., Strom T.B., Weir M.R., Tinley N.L. Late mortality and morbidity in recipients of long-term renal allografts. Transplantation 1982, 34(6):347-351.
2. Toussaint C., Kinnaert P., Vereerstraeten P. Late mortality and morbidity five to eighteen years after kidney transplantation. Transplantation 1988, 45(3):554-557.
3. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002, 346:580-590.
4. Wyatt C., Arons R. The burden of acute renal failure in nonrenal solid organ transplantation. Transplantation 2004, 78(9):1351-1355.
5. Golshayan D., Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl Immunol 2008, 20:21-28.
6. Vanrenerghem Y., Claes K., Montagino G., Fieuws S., Maes B., Villa M., et al. Risk factors for cardiovascular event after successful renal transplantation. Transplantation 2008, 85(2):209-216.
7. Nankivell B., Alexander S. Rejection of the kidney allograft. N Engl J Med 2010, 363:1451-1462.
8. Borchers A., Perez R., Kaysen G., Ansari A.A., Gershwin E.M. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol 1999, 7:75-82.
9. Kutinova A., Woodward R.S., Ricci J.F., Brennan D.C. The incidence and costs of sepsis and pneumonia before and after renal transplantation in the United States. Am J Transplant 2006, 6:129-139.
10. Husain S., Pietrangeli C., Zeevi A. Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 2009, 21:1-9.
11. Howell D.N., Smith S.R., Butterly D.W., Klassen P.S., Krigman H., Burchette J.L., et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999, 68(9):1279-1288.
12. Park J.M., Choi M.G., Kim S.W., Chung I.S., Yang C.W., Kim Y.S., et al. Increased incidence of colorectal malignancies in renal transplant recipients: a case control study. Am J Transplant 2010, 10(9):2043-2050.
13. Amital A., Shitrit D., Raviv Y., Bendayan D., Sahar G., Bakal Ilana, et al. Development of malignancy following lung transplantation. Transplantation 2006, 81(4):547-551.
14. Buell J.F., Gross T.G., Woodle E.S. Malignancy after transplantation. Transplantation 2005, 80(2S):S254-S264.
15. Kasiske B.L., de Mattos A., Flechner S.M., et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008, 8:1384-1392.
16. Troppmann C., Pierce J.L., Gandhi M.M., et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003, 76:426-429.
17. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
18. Webster A.C., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331:810.
19. Ekberg H., Grinyo J., Nashan B., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007, 7:560-570.
20. Rostaing L., Cantarovich D., Mourad G., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005, 79:807-814.
21. Kowalski R., Post D., Schneider M.C., Britz J., Thomas J., Deierhoi M., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003, 17:77-88.
22. Kowalski R., Post D., Mannon R.B., Sebastian A., Wright H.I., Sigle G., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
23. Israeli M., Yussim A., Mor E., Sredni B., Klein T. Preceeding the rejection: In search for a comprehensive post-transplant immune monitoring platform. Transpl Immunol 2007, 18:7-12.
24. Israeli M., Ben-Gal T., Yaari V., Valdman A., Matz I., Medalion B., et al. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 2010, 89:968-976.
25. Xue F., Zhang J., Han L., Li Q., Xu N., Zhou, et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. Transplantation 2010, 89:620-626.
26. Husain S., Raza K., Pilewski J.M., Zaldonis D., Crespo M., Toyod Y., et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 2009, 87:1852-1857.
27. Bhorade S.M., Janata K., Vigneswaran W.T., Alex C.G., Garrity E.R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008, 27:990-994.
28. Cadillo-Chávez R., de Echegaray S., Santiago-Delpin E.A., Rodriguez-Trinidad A.T., Camacho-Carrazo B., Alfaro T., et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006, 38:918-920.
29. Hashimoto K., Miller C., Hirose K., Diago T., Aucejo F., Quintini C., et al. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2009, Article first published online: 28 DEC 2009. 10.1111/j.1399-0012.2009.01169.x.
30. Britz J., Post D., Hawkins D., Kowalski R. Extremely low immune function is associated with increased risk of mortality in solid organ transplant recipients. Paper presented at: Nantes Actualites Transplantation 2007, Nantes, France.
31. United States Department of Health and Human Services. K013169; Cylex Immune Cell Function Assay, April 02, 2002.